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Abstract
Aim: Obesity is generally linked to complications in lipid metabolism and oxidative stress. The aim
of this study was to compare the effect of a proprietary extract of Cissus quadrangularis (CQR-300)
to that of a proprietary formulation containing CQR-300 (CORE) on weight, blood lipids, and
oxidative stress in overweight and obese people.
Methods: The first part of the study investigated the in vitro antioxidant properties of CQR-300
and CORE using 3 different methods, while the second part of the study was a double-blind placebo
controlled design, involving initially 168 overweight and obese persons (38.7% males; 61.3%
females; ages 19–54), of whom 153 completed the study. All participants received two daily doses
of CQR-300, CORE, or placebo and were encouraged to maintain their normal levels of physical
activity. Anthropometric measurements and blood sampling were done at the beginning and end of
the study period.
Results: CQR-300 as well as CORE exhibited antioxidant properties in vitro. They also acted as in
vivo antioxidants, bringing about significant (p < 0.001) reductions in plasma TBARS and carbonyls.
Both CQR-300 and CORE also brought about significant reductions in weight, body fat, total
cholesterol, LDL-cholesterol, triglycerides, and fasting blood glucose levels over the respective
study periods. These changes were accompanied by a significant increase in HDL-cholesterol levels,
plasma 5-HT, and creatinine.
Conclusion:  CQR-300 (300 mg daily) and CORE (1028 mg daily) brought about significant
reductions in weight and blood glucose levels, while decreasing serum lipids thus improving
cardiovascular risk factors. The increase in plasma 5-HT and creatinine for both groups
hypothesizes a mechanism of controlling appetite and promoting the increase of lean muscle mass
by  Cissus quadrangularis, thereby supporting the clinical data for weight loss and improving
cardiovascular health.
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Background
The incidence of obesity in adults as well as children is on
an increase globally. Once considered a problem of devel-
oped countries, this global epidemic also affects develop-
ing countries. Coupled to this epidemic are obesity-
related complications such as cardiovascular disease,
stroke, depression, and Type-2 diabetes, which are spread-
ing rapidly across poor and middle-income countries,
where infectious diseases and malnutrition have previ-
ously overshadowed such illnesses [1]. Obesity is a princi-
pal causative factor of metabolic syndrome [2-6]. The
coexistence of these metabolic syndromes (hyperglyc-
emia, dyslipidemia, and hypertension in the same indi-
vidual) is a growing medical problem in industrialized
countries [6-9]. It has been reported that obesity may
induce systemic oxidative stress and that increased oxida-
tive stress in accumulated fat is associated with dysregula-
tion of adipocytokines and development of metabolic
syndrome [6]. Oxidative stress has been shown to be
involved in the process of atherogenesis [10], ischemic
heart disease [11], obesity [6], metabolic syndrome or
syndrome X, diabetes [12,13], as well as in immunodefi-
ciency [14]. The stability of tissues against oxidative stress
is however enhanced by antioxidant compounds, which
could be present in the diet [15]. Antioxidants have also
been shown to be very effective in inhibiting the oxidation
of LDL and scavenging of free radicals and reactive oxygen
species in vitro [16-20]. These compounds are present in
fruits and vegetables, which contain natural antioxidants,
and are known to delay the onset of atherogenesis.
Cissus quadrangularis (Linn) has been used by common
folk in India for promoting the fracture healing process. It
has been prescribed in Ayurveda as an alterative,
anthelmintic, dyspeptic, digestive, tonic, analgesic in eye
and ear diseases, and in the treatment of irregular men-
struation and asthma. In Cameroon, the whole plant is
used in oral re-hydration, while the leaf, stem, and root
extracts of this plant are important in the management of
various ailments. Earlier works on Cissus quadrangularis
report its effectiveness on the management of obesity and
complications associated with metabolic syndrome [21],
as well as its antioxidant and free radical scavenging activ-
ity  in vitro [22,23]. Various formulations now contain
extracts of Cissus quadrangularis in combination with other
compounds, used for the purpose of management of over-
weight and obesity, as well as complications resulting
from these conditions, notably metabolic syndrome (syn-
drome X). Phytochemical analyses of Cissus quadrangularis
revealed high contents of ascorbic acid, carotene, anabolic
steroidal substances, and calcium. The stem contains two
asymmetric tetracyclic triterpenoids, and two steroidal
principles. The presence of β-sitosterol, δ-amyrin, δ-amy-
rone, and flavanoids (quercetin) has also been reported
[24,25], all these components having potentially different
metabolic and physiologic effects.
Although different uses of Cissus quadrangularis have been
investigated, [26,27] the antioxidant potential of various
Cissus quadrangularis formulations have not been evalu-
ated in the modulation of obesity-induced oxidative
stress. It was for this reason that the present study was
designed, using a Cissus quadrangularis formulation
(CORE) and CQR-300 (a standardized extract of Cissus
quadrangularis, 2.5 % keto-steroids, and 15% soluble
plant fiber).
Methods
The study was approved by the Cameroon National Ethics
Board. The purpose, nature, and potential risks of the
study were explained to all participants, who gave their
written informed consent before participation. The study
was conducted in accordance with the Helsinki Declara-
tion (1983 version).
Sample
CORE (Table 1) was obtained from Soy Labs, LLC., Fair-
field, California, USA;. CQR-300, a standardized extract of
Cissus quadrangularis containing 2.5% keto-steroids and
15% soluble plant fiber (Gateway Health Alliances, Inc,
Fairfield, California, USA).
In vitro antioxidant potential of the CORE formulation 
and CQR-300
Both CORE and CQR-300 were dissolved in acidified
methanol prepared as previously described by Agbor et al.
[19] for the in vitro antioxidant study. Three methods were
used for the determination of antioxidant potential: Folin
(polyphenol content), ferric reducing antioxidant power
(FRAP, antioxidant power), 1,1-Diphenyl-2-picrilhydra-
zyl (DPPH, redical scavenging potential).
Polyphenol content
The Folin Ciocalteu reagent (Sigma Chemical Co., St
Louis, MO, USA) was used to determine the concentration
of polyphenol as a measure of antioxidant potential of
CORE and CRQ-300. The reagent was diluted 10 times
before used as described by Singleton et al. [28]. The
absorbance was measured at 750 nm (Genesys Spectronic
20).
Ferric Reducing Antioxidant Power (FRAP) was measured
as earlier described by Benzie and Strain. [29]. In brief,
2000 μl of freshly prepared FRAP reagent (10 parts of 300
mM acetate buffer (pH 3.6), 1 part of 10 mM TPTZ
(Sigma, in 400 mM HCL), and 1 part of 20 mM ferric
chloride). After an initial incubation for 15 minutes at
37°C, the absorbance was read at 593 nm.Lipids in Health and Disease 2007, 6:4 http://www.lipidworld.com/content/6/1/4
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Scavenging potential against 1,1-Diphenyl-2-picrilhydra-
zyl (DPPH) measured the ability of the extracts to scav-
enge free radicals. 20 μl of extract was introduced into 2
ml methanolic solution of DPPH (0.3 mM) and kept in
the dark for 30 minutes. The extract was replaced by meth-
anol for the control, and catechin was used as the stand-
ard. The absorbance was read at 517 nm, and the
antioxidant content and percentage inhibition of the
extract calculated as earlier described by Yen and Duh,
[30].
In all three methods mentioned above, measurements
were done in triplicates.
In vivo study
Participants
A total of 168 overweight, obese, and normal weight par-
ticipants aged between 19 and 50 years were selected from
a group responding to a radio and poster advert. The BMIs
of participants ranged from 25.0 to 48.7, and their
weights ranged from 70.6 to 142 kg. After physical exam-
ination, which included measurement of blood pressure,
participants with unusually elevated fasting blood glucose
levels, those who were pregnant or lactating, as well as
those on any form of weight-reducing medication were
excluded from the study. Also excluded were participants
who were involved in intense exercise programs, had
medical conditions known to affect serum lipids, or had a
history of drug or alcohol abuse. A total of 153 partici-
pants completed the study, while 15 participants dropped
out of the study for personal reasons (7 moved out of
town or had to travel during study period; 4 participants
thought they had lost enough weight; while 4 participants
were on malaria treatment and were excluded before the
end of the study period).
Trial protocol
The study was double-blind placebo controlled, with the
168 overweight, obese, or normal weight participants of
both sexes (between 19 and 50 years) distributed as out-
lined in Table 2. The participants who were either on their
normal diet or on an energy restricted (2100 Kcal/day)
diet, received two daily doses in the form of capsules of
CORE for 8 weeks, and CQR-300 or placebo for 6 weeks.
The capsules were identical in shape, color, and appear-
ance, with neither the participants nor researchers know-
ing what capsule they received. Side effects were solicited
on each weekly visit. Body weight and percentage body fat
were determined in 12-hour fasted participants using a
Tanita™ scale. Height was measured with a stadiometer to
the nearest 0.5 cm. Blood samples were obtained at the
start and end of the trial period after a 12-hour overnight
fast, into heparinized tubes, for the measurement of LDL
oxidation (TBARS) [31] and protein carbonyl [32] con-
tent, total cholesterol, triacylglycerol, HDL-cholesterol,
LDL-cholesterol, and glucose (cholesterol Infinity, triglyc-
Table 2: Distribution of participants into treatment groups. The number given in parentheses represents the participants whose 
complete measurements were done over the study period.
Group No. Participants Treatment No. of Participants
1 Males/Females BMI>30 Placebo 6 weeks (2100 Kcal/day diet) 33 (32)
2 Males/Females BMI>30 CORE 8 weeks (no dietary restriction) 33 (30)
3 Males/Females BMI>30 CORE 8 weeks (2100 Kcal/day diet) 35 (31)
4 Males/Females BMI>30 CQR-300 6 weeks (2100 Kcal/day diet) 35 (32)
5 Males/Females BMI 25–29.9 CORE 8 weeks (no dietary restriction) 32 (28)
Table 1: Detailed composition of the cissus formulation (CORE).
Item Description Active Amount
Per Capsule (mg)
Amount of Active Per Day
(2 capsules) (mg)
Cissus quadrangularis 5% ketosteroids 7.5 15
ChromeMate* Niacin-Bound Chromium (10% Cr) – Concentrate 0.15 0.3
Green Tea Extract (High Caffeine) 40% Polyphenols, 22% EGCG, 40% Caffeine 100 200
Selenium 0.5% l-Selenomethionine 0.06 0.12
AlbumaSoy** Soy Albumin 50 100
Vitamin B6 pyridoxine hydrochloride 50 100
Vitamin B12 cyanocobalamin 0.05 0.1
Folic Acid Folic acid 0.4 0.8
Total Per Unit 104.08 265.645
*ChromeMate is a trademark of InterHealth N.I.
**AlbumaSoy is trademark of Soy Labs, LLCLipids in Health and Disease 2007, 6:4 http://www.lipidworld.com/content/6/1/4
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eride Infinity, EZ HDL™ cholesterol, EZ LDL™ cholesterol,
Glucose Trinder) from SIGMA Diagnostics. Serotonin was
measured using an enzyme immunoassay method (Serot-
onin EIA kit, BioSource Europe S.A, Belgium), creatinine
by a modification of the method of Bartels et al. [33],
while MDA was measured by a standard established
method [34].
Statistical analyses
Statistical Package for the Social Sciences (SPSS) [35] soft-
ware was used for all statistical analysis. The data were pre-
sented as means ± SD. The statistical difference between
samples was assessed by a Student's t-test for normal dis-
tribution or the Mann-Whitney test for non-normal distri-
bution, after ANOVA testing of all the groups showed that
significant differences existed. Paired Student's t-test was
carried out on the start and end values of all the groups.
Results
In vitro fantioxidant potential of CORE and CQR-300
The in vitro antioxidant capacity of CORE was significantly
(p < 0.01) higher than that of CQR-300 irrespective of the
method of analysis used. Considering the composition of
CORE (Table 1), it is likely that the other components
present act synergistically with the Cissus quadrangularis
extract present (Table 3).
Table 4 presents the effect of CORE and CQR-300 on the
oxidative stress parameter (TBARS and carbonyls). CORE
was more effective in reducing oxidative stress than CQR-
300, the reduction being more obvious in the diet-
restricted group. It significantly (p < 0.01) reduced the for-
mation of TBARS and carbonyls compared to CQR-300.
Effect of CORE and CQR-300 on body weight
Obese participants, who received CQR-300 (300 mg
daily), had significantly (p < 0.05) greater reduction in
body weight compared to those on placebo (Table 5). This
reduction in body weight corresponded to a 5.4 % reduc-
tion in BMI. CORE had a more significant (p < 0.01) effect
(8.5% reduction for participants on an energy restricted
diet) on the weight of participants compared to CQR-300.
There was no significant net change in weight in partici-
pants on placebo during the study period.
Table 6 presents the effect of CORE and CQR-300 on
blood lipids and fasting blood glucose levels. For partici-
pants on a restricted diet, six weeks use of CQR-300
reduced plasma total cholesterol by 18.0%, LDL-choles-
terol by 29.0%, triacylglycerol by 21.7%, and fasting
blood glucose by 14.6%. This treatment also increased the
concentration of HDL-cholesterol by 21.1%. On the other
hand, CORE (group 3) reduced the concentration of
plasma total cholesterol by 26.0%, LDL-cholesterol by
32.4%, triacylglycerol 28.0%, and fasting blood sugar
16.1%. The CORE formulation also increased HDL cho-
lesterol by 43.0%. The above mentioned changes were less
obvious in participants whose diets were not restricted.
The effect of CORE and CQR-300 on malondialdehyde
(MDA), serum serotonin, and creatinine levels are pre-
sented in Table 7. CQR-300 significantly (p < 0.05)
reduced the concentration of plasma MDA. This effect was
accompanied by a slight increase in the urinary concentra-
tion of MDA though not significant. CQR-300 also signif-
icantly (p < 0.05) increased the concentration of plasma
5-HT by 53.3% and plasma creatinine levels by 23.5%. An
increase in 5-HT of 17.0% was also observed in the pla-
cebo group, while CORE (group 3) showed a significant
increase of 39.1%. As such results for 5-HT and creatinine
were significantly (p < 0.05) lower for CORE than CQR-
300.
Discussion
The role of antioxidants from natural products in degen-
erative disease has attracted more interest on natural
products research. In this study, we evaluated the antioxi-
dant potential of CORE and CQR-300 on obesity-induced
oxidative stress. The parent plant in these two formula-
tions is Cissus quandrangularis. The formulation had a
higher in vitro antioxidant potential than CQR-300 irre-
spective of the method used for the assay. The high anti-
oxidant potential of CORE may be due to its composition.
It contains some tea polyphenols and selenium that are
potential antioxidants and thus complement the antioxi-
dant potential of the parent plant in this formulation (Cis-
sus quandrangularis). On the other hand, CQR-300 is a
standardized extract of Cissus quandrangularis and no anti-
oxidant was added to it.
Table 3: In vitro antioxidant capacity of the CORE and CQR-300 (mg of catechin equivalent/gram dry weight) by FRAP, Folin, and 
DPPH methods.
FRAP Antioxidant (mg/g) Folin Total Polyphenol (mg/g) DPPH Antioxidant (mg/g)
CORE 22.67 ± 4.58 56.70 ± 6.12 8.46 ± 1.30
CQR-300 15.85 ± 3.08* 42.33 ± 3.21* 5.97 ± 0.66*
*p < 0.01 compared to the cissus formulation for each method.L
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Table 4: The effect of the CORE and CQR-300 extracts on the concentrations of TBARS and carbonyls.
Group 1
BMI>30
Placebo
(2100 Kcal/day diet)
Group 2
BMI>30
CORE
(no dietary restriction)
Group 3
BMI>30
CORE
(2100 Kcal/day diet)
Group 4
BMI>30
CQR-300
(2100 Kcal/day diet)
Group 5
BMI 25–29.9
CORE
(no dietary restriction)
Time (weeks) T = 0 T = 6 T = 0 T = 8 T = 0 T = 8 T = 0 T = 6 T = 0 T = 8
TBARS (umol/L) 1.42 ± 0.51 1.60 ± 0.38 1.66 ± 0.56 0.87 ± 0.53** 1.78 ± 0.38 0.72 ± 0.35**† 1.84 ± 0.51 0.98 ± 0.18** 1.06 ± 0.24 0.66 ± 0.13**†
Carbonyls (nmol/mg protein) 1.95 ± 0.73 2.09 ± 0.68 2.03 ± 0.39 0.98 ± 0.39** 1.96 ± 0.40 0.84 ± 0.27**† 2.06 ± 0.28 1.10 ± 0.34** 0.94 ± 0.20 0.77 ± 0.36**†
**p < 0.001 compared to T = 0; †p < 0.01 compared to CQR-300 (Group 4).
Table 5: Effect oftheCORE and CQR-300 on body weight, BMI, and Body fat
Group 1
BMI>30
Placebo
(2100 Kcal/day diet)
Group 2
BMI>30
CORE
(no dietary restriction)
Group 3
BMI>30
CORE
(2100 Kcal/day diet)
Group 4
BMI>30
CQR-300
(2100 Kcal/day diet)
Group 5
BMI 24–29.9
CORE
(no dietary restriction)
Time (weeks) T = 0 T = 6 T = 0 T = 8 T = 0 T = 8 T = 0 T = 6 T = 0 T = 8
Weight (kg) 112.4 ± 2.6 113.6 ± 2.0 (1.1) 95.8 ± 11.8 89.2 ± 9.2 (6.9)* 95.3 ± 14.6 87.2 ± 8.9 (8.5)**† 118.6 ± 3.8 113.8 ± 2.5 (4.0)* 76.3 ± 6.8 72.5 ± 4.7 (5.0)*
BMI (kg/m2) 38.1 ± 1.1 38.0 ± 0.9 37.7 ± 6.3 34.6 ± 8.6 37.5 ± 4.7 33.8 ± 6.9 38.8 ± 1.0 36.7 ± 3.4 27.3 ± 2.5 26.3 ± 3.0
Body fat (%) 43.6 ± 1.6 42.8 ± 2.1 46.5 ± 3.1 43.7 ± 2.4 48.1 ± 4.4 44.3 ± 2.1 44.3 ± 5.4 42.1 ± 3.6 35.9 ± 2.2 34.2 ± 3.0
Values are means ± SE.
*p < 0.05, **p < 0.01, compared to placebo,†p < 0.01 compared to CQR-300 (Group 4), () = percentage change in weight.L
i
p
i
d
s
 
i
n
 
H
e
a
l
t
h
 
a
n
d
 
D
i
s
e
a
s
e
 
2
0
0
7
,
 
6
:
4
h
t
t
p
:
/
/
w
w
w
.
l
i
p
i
d
w
o
r
l
d
.
c
o
m
/
c
o
n
t
e
n
t
/
6
/
1
/
4
P
a
g
e
 
6
 
o
f
 
8
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 6: Effect of the CORE and CQR-300 on blood lipids and fasting blood glucose
Group 1
BMI>30
Placebo
(2100 Kcal/day diet)
Group 2
BMI>30
CORE
(no dietary restriction)
Group 3
BMI>30
CORE
(2100 Kcal/day diet)
Group 4
BMI>30
CQR-300
(2100 Kcal/day diet)
Group 5
BMI 24–29.9
CORE
(no dietary restriction)
Time (weeks) T = 0 T = 6 T = 0 T = 8 T = 0 T = 8 T = 0 T = 6 T = 0 T = 8
Total Cholesterol (mg/dL) 136.3 ± 9.0 138.3 ± 11.1 159.1 ± 14.6 116.2 ± 9.7* 171.0 ± 15.9 126.5 ± 7.9 *† 138.3 ± 13.8 113.4 ± 4.5* 152.6 ± 8.8 123.0 ± 4.7*
LDL-cholesterol (mg/dL) 88.4 ± 5.9 88.2 ± 5.9 99.8 ± 6.5 81.4 ± 1.7 116.6 ± 5.4 78.8 ± 3.3 92.7 ± 7.0 65.8 ± 3.4 101.6 ± 1.9 74.8 ± 0.9
HDL-cholesterol (mg/dL) 27.3 ± 2.2 25.8 ± 3.1 36.6 ± 4.7 55.1 ± 6.4* 38.6 ± 10.5 55.2 ± 8.6*† 25.6 ± 4.8 31.0 ± 3.9 44.4 ± 7.7 52.0 ± 8.1
Triacylglycerol (mg/dL) 93.6 ± 4.8 90.5 ± 10.4 156.0 ± 16.8 95.6 ± 8.1 144.9 ± 43.3 104.3 ± 26.2*† 93.8 ± 9.7 73.4 ± 6.0*** 117.4 ± 9.8 99.8 ± 11.2
Fasting Blood glucose (mg/dL) 93.6 ± 7.2 89.4 ± 10.1 101.3 ± 8.6 87.7 ± 10.0 102.4 ± 1.8 85.9 ± 5.2 91.8 ± 6.9 78.4 ± 11.2 93.3 ± 10.2 82.7 ± 7.2
Values are means ± SE, comparing starting point to end point, significant differences were at *p < 0.05, **p < 0.01 and ***p < 0.001 for the same treatment.
Table 7: Effect of the CORE andCQR-300 on plasma and urinary malondialdehyde, 5-HT, and plasma creatinine levels
Group 1
BMI>30
Placebo
(2100 Kcal/day diet)
Group 2
BMI>30
CORE
(no dietary restriction)
Group 3
BMI>30
CORE
(2100 Kcal/day diet)
Group 4
BMI>30
CQR-300
(2100 Kcal/day diet)
Group 5
BMI 24–29.9
CORE
(no dietary restriction)
Time (weeks) T = 0 T = 6 T = 0 T = 8 T = 0 T = 8 T = 0 T = 6 T = 0 T = 8
Plasma MDA (μmol/L) 1.8 ± 0.1 1.7 ± 0.1 1.8 ± 0.6 1.0 ± 0.5* 1.9 ± 0.9 1.1 ± 0.6 *† 1.6 ± 0.2 1.0 ± 0.4* 1.8 ± 0.3 1.2 ± 0.5*
Urinary MDA (μmol/day) 3476.2 ± 211.7 3492.2 ± 188.4 3864.3 ± 238.4 4325.1 ± 167.5* 4022.1 ± 148.1 4485.8 ± 203.3 3416.2 ± 110.9 3581.5 ± 200.2 3593.8 ± 116.5 3971.0 ± 104.5
Plasma 5-HT (mgl/dl) 30.6 ± 1.9 35.8 ± 2.1 32.5 ± 1.9 42.4 ± 3.4* 38.4 ± 1.5 53.4 ± 3.6† 35.4 ± 1.7 54.3 ± 2.9* 33.1 ± 3.7 43.2 ± 2.1*
Plasma creatinine (mg/dl) 25.7 ± 3.8 27.3 ± 1.4 25.9 ± 1.8 31.8 ± 2.1 24.4 ± 3.2 28.9 ± 1.2 27.2 ± 2.2 33.6 ± 1.4* 29.0 ± 0.8 33.8 ± 1.2
Values are means ± SD, comparing starting point to end point, significant differences were at *p < 0.05 for the same treatment.Lipids in Health and Disease 2007, 6:4 http://www.lipidworld.com/content/6/1/4
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Obesity may induce systemic oxidative stress, and
increased oxidative stress in accumulated fat is one of the
underlying causes of dysregulation of adipocytokines and
development of metabolic syndrome [6]. Oxidative stress
plays critical roles in the pathogenesis of various diseases
[36]. In order to investigate if oxidative stress was
increased in the obese participants, we measured lipid
peroxidation (which represent the plasma TBARS) and the
carbonyl compounds as markers of oxidative injury,
which correlates with the BMI. The high plasma concen-
tration of TBARS and carbonyl compounds was an indica-
tion of oxidative stress in the obese and overweight
participants. These concentrations were significantly (p <
0.01) reduced after treatment, with CORE being more
effective than CQR-300. These samples may function
through two mechanisms: either by scavenging free radi-
cals to reduce oxidative stress, or by clearing the plasma of
the products that are themselves potential oxidants. These
activities may be attributed to the polyphenols present in
the different formulations.
The use of CORE and CQR-300 during the study period
brought about a significant reduction in the weight and
BMI of obese patients. This loss in weight was comparable
to that observed with cissus studies [21], sibutramine for
one year [37], and orlistat for 6 months or 1 year [38,39].
This reduction in BMI was accompanied by an increase in
HDL-cholesterol, and corroborates earlier work that
showed an inverse relation between BMI and HDL-choles-
terol, the latter imparting possible health benefits in over-
weight and obese people [40,41]. The increase in the
concentration of HDL-cholesterol and a decrease in the
concentration of LDL-cholesterol could lead to a lowering
of the atherogenicity and therefore a significant reduction
in the potential incidence of coronary heart disease [42]
(54% reduction of risk for a 0.6 mmol/L reduction of
serum cholesterol) [43]. A reduction of fasting blood glu-
cose levels as well as MDA levels have been previously
reported to accompany weight loss in obese subjects [39].
The above observation could be linked to an increase in
circulating creatinine and serotonin over the eight-week
trial period. Serotonin is known to have a positive effect
on mood and to reduce binge eating, which is common in
obese people. Several previous studies [44,45] have
shown a direct link between serotonin levels and weight
loss. On the other hand, an increase in creatinine concen-
trations parallels an increase in lean muscle mass and a
probable reduction in body fat.
Furthermore,  in vitro studies (submitted in a different
publication) show the ability of Cissus quadrangularis
extracts to inhibit pancreatic lipase by approximately
60%, alpha-amylase by approximately 90%, as well as
alpha-glucosidase by approximately 39%, all of which
could contribute to weight reduction in obesity.
Conclusion
The CORE and CQR-300 (300 mg daily) brought about a
significantly greater weight loss than placebo during the
study period in obese individuals. This was accompanied
by a significant improvement in the lipid profiles, blood
sugar profiles, and serotonin profiles of study partici-
pants. They could have additional properties as antioxi-
dants against oxidative stress in obese individuals. Thus,
CQR-300 as well as CORE possesses antioxidant and free
radical scavenging properties that could have applications
in metabolic as well as other physiological complications
in which there is an increase in oxidative stress.
These new findings warrant further exploration into the
active phytonutrients of Cissus quadrangularis and the
potential of its newly discovered weight loss and cardio-
vascular health benefits.
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